ES2728072T3 - Marcadores genéticos para aumento de peso inducido por antipsicóticos y sus métodos de uso - Google Patents

Marcadores genéticos para aumento de peso inducido por antipsicóticos y sus métodos de uso Download PDF

Info

Publication number
ES2728072T3
ES2728072T3 ES14854407T ES14854407T ES2728072T3 ES 2728072 T3 ES2728072 T3 ES 2728072T3 ES 14854407 T ES14854407 T ES 14854407T ES 14854407 T ES14854407 T ES 14854407T ES 2728072 T3 ES2728072 T3 ES 2728072T3
Authority
ES
Spain
Prior art keywords
seq
subject
polymorphisms
weight gain
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14854407T
Other languages
English (en)
Spanish (es)
Inventor
Clement C Zai
James L Kennedy
Daniel J Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Addiction and Mental Health
Original Assignee
Centre for Addiction and Mental Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre for Addiction and Mental Health filed Critical Centre for Addiction and Mental Health
Application granted granted Critical
Publication of ES2728072T3 publication Critical patent/ES2728072T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
ES14854407T 2013-10-17 2014-10-17 Marcadores genéticos para aumento de peso inducido por antipsicóticos y sus métodos de uso Active ES2728072T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361892094P 2013-10-17 2013-10-17
PCT/CA2014/051000 WO2015054792A1 (en) 2013-10-17 2014-10-17 Genetic markers for antipsychotic induced weight gain and methods for use thereof

Publications (1)

Publication Number Publication Date
ES2728072T3 true ES2728072T3 (es) 2019-10-22

Family

ID=52827506

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14854407T Active ES2728072T3 (es) 2013-10-17 2014-10-17 Marcadores genéticos para aumento de peso inducido por antipsicóticos y sus métodos de uso

Country Status (12)

Country Link
US (1) US10301678B2 (https=)
EP (2) EP3058106B1 (https=)
JP (1) JP6524073B2 (https=)
KR (1) KR102252926B1 (https=)
CN (1) CN106029901A (https=)
AU (1) AU2014336928B2 (https=)
CA (1) CA2943951C (https=)
ES (1) ES2728072T3 (https=)
IL (1) IL245159B (https=)
PT (1) PT3058106T (https=)
SG (1) SG11201602998QA (https=)
WO (1) WO2015054792A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210033619A1 (en) * 2018-02-09 2021-02-04 Metabolomic Diagnostics Limited Methods of predicting pre term birth from preeclampsia using metabolic and protein biomarkers
CN110317868B (zh) * 2019-08-09 2020-05-19 新疆医科大学第二附属医院 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法
CN117547526A (zh) * 2023-10-24 2024-02-13 首都医科大学附属北京朝阳医院 γ-氨基丁酸GABA在制备防治奥氮平诱发的不良反应药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
JP4071277B2 (ja) 1993-11-12 2008-04-02 ピーエイチアールアイ・プロパティーズ・インコーポレーテッド 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット
US20030104453A1 (en) 2001-11-06 2003-06-05 David Pickar System for pharmacogenetics of adverse drug events
US8012718B2 (en) 2006-03-31 2011-09-06 Genomas, Inc. Physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs
US20070292962A1 (en) * 2006-04-10 2007-12-20 Duke University Methods and compositions for genetic markers for autism
US7795033B2 (en) 2007-03-19 2010-09-14 The United States Of America As Represented By The Department Of Health And Human Services Methods to predict the outcome of treatment with antidepressant medication
US8476012B2 (en) 2008-04-18 2013-07-02 Genomas, Inc. Physiogenomic method for predicting metabolic and cardiovascular side effects of thiazolidinediones
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
JP2015501652A (ja) 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇａｂｒ−ａ２診断

Also Published As

Publication number Publication date
IL245159A0 (en) 2016-06-30
CA2943951A1 (en) 2015-04-23
US20160237499A1 (en) 2016-08-18
CA2943951C (en) 2022-05-31
JP2016534715A (ja) 2016-11-10
CN106029901A (zh) 2016-10-12
IL245159B (en) 2020-10-29
EP3058106A1 (en) 2016-08-24
SG11201602998QA (en) 2016-05-30
EP3561076A1 (en) 2019-10-30
KR102252926B1 (ko) 2021-05-20
AU2014336928B2 (en) 2020-07-16
JP6524073B2 (ja) 2019-06-05
US10301678B2 (en) 2019-05-28
KR20160098188A (ko) 2016-08-18
PT3058106T (pt) 2019-05-30
EP3058106B1 (en) 2019-02-27
WO2015054792A1 (en) 2015-04-23
EP3058106A4 (en) 2017-06-07

Similar Documents

Publication Publication Date Title
Hu et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder
Martucci et al. N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels
Piton et al. Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia
Ohtsuki et al. Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia
Domschke Clinical and molecular genetics of psychotic depression
US10098893B2 (en) Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
Wong et al. Association between schizophrenia and the syntaxin 1A gene
ES2728072T3 (es) Marcadores genéticos para aumento de peso inducido por antipsicóticos y sus métodos de uso
KR20160111925A (ko) 자살 위험과 연관된 유전적 마커 및 그의 사용 방법
Kang et al. Genetic variants of GRIA1 are associated with susceptibility to schizophrenia in Korean population
Rothe et al. Association study of serotonin-2A receptor gene polymorphism and panic disorder in patients from Canada and Germany
Bishop et al. Association between type‐three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia
AU2014336928A1 (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
Liu et al. The YWHAE gene confers risk to major depressive disorder in the male group of Chinese Han population
Morita et al. The glycine transporter 1 gene (GLYT1) is associated with methamphetamine‐use disorder
CA2664366C (en) Slc1a1 antipsychotic drug response markers
Lohoff et al. Association between polymorphisms in the vesicle-associated membrane protein-associated protein A (VAPA) gene on chromosome 18p and bipolar disorder
Kayahan et al. The lack of association between catechol-O-methyltransferase (COMT) Val108/158Met and brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms and schizophrenia in a group of Turkish population
US7368264B2 (en) SLC1A1 marker for anxiety disorder
KR101559626B1 (ko) 정동 장애 치료제의 치료반응 예측용 키트
HK1224705B (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
HK1224705A1 (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
Theodoridou et al. mRNA levels of HPA axis mediators in drug-naïve, first episode psychosis patients before and after antipsychotic treatment
US20070048767A1 (en) Marker for a Psychosis or a Mood Disorder
Zai et al. Weak association of the platelet-derived growth factor beta (PDGFB) and PDGF receptor beta (PDGFRB) genes with schizophrenia and schizoaffective disorder